Arcturus Therapeutics (NASDAQ: ARCT) reported Q2 EPS of ($0.84), $0.21 better than the analyst estimate of ($1.05). Revenue for the quarter came in at $2.96 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.